Toward Probabilistic Analysis of Guidelines by Hommersom, Arjen
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is an author's version which may differ from the publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/92503
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Toward Probabilistic Analysis of Guidelines
Arjen Hommersom
Radboud University Nijmegen
Institute for Computing and Information Sciences
Nijmegen, The Netherlands
arjenh@cs.ru.nl ?
Abstract. In the formal analysis of health-care, there is little work that
combines probabilistic and temporal reasoning. On the one hand, there
are those that aim to support the clinical thinking process, which is
characterised by trade-off decision making taking into account uncer-
tainty and preferences, i.e., the process has a probabilistic and decision-
theoretic flavour. On the other hand, the management of care, e.g., guide-
lines and planning of tasks, is typically modelled symbolically using tem-
poral, non-probabilistic, methods. This paper proposes a new framework
for combining temporal reasoning with probabilistic decision making.
The framework is instantiated with a guideline modelling language com-
bined with probabilistic pharmokinetics and applied to the treatment of
diabetes mellitus type 2.
1 Introduction
Clinical guidelines are highly structured documents providing appropriate stan-
dards of care. Recommendations of clinical guidelines are based around actions,
also sometimes referred to as tasks or interventions, that physicians are advised
to perform when treating specific groups of patients. If there is only one possible
action in the care pathway, the situation is relatively easy. For many diseases,
however, there are at least several actions that have to be performed. In order
to model such care pathways, expressive formalisms were developed such as As-
bru, PROforma, and GLARE (see [2]). These languages are best characterised
by the term ‘task-network models’, as they model the guideline as a network of
component tasks that unfold over time [11].
In order to ensure quality of these guidelines, several symbolic analysis ap-
proaches have been proposed, such as simulation and verification, e.g., using
formal methods for checking that resulting guidelines comply to certain quality
criteria (see, e.g., [7]). Whereas the recommendations can be looked upon as
symbolic and logical entities, the underlying knowledge, typically medical evi-
dence, involves uncertainty. So far, this aspect of a guideline has been largely
ignored, but is required for a deeper analysis of the quality of guidelines.
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The representation of uncertainty is particularly important if one wants to
support the guideline development process. As far as we are aware, there are no
knowledge representation formalisms specifically designed for this task. Indeed,
the main challenge for such a representation is to integrate knowledge underlying
guidelines with medical decision making taking into account uncertainty derived
from the evidence. A complicating factor is that the current process of developing
recommendations from uncertain knowledge is hardly clear. For example, the
‘The guidelines manual’ by the British NHS [10] states the following about
recommendations: “If (the guideline) combines consideration of several possible
interventions, it may include discussion of the position of an intervention within
a pathway of care”. There is no way to decide how to determine the position of
the intervention within a pathway of care. In this paper, a language is introduced
for exploring different possible combinations of treatments and to consider their
outcomes. This also opens up a new possibility for personalisation of medicine
as different treatment options can be explored for specific patients.
This paper is organised as follows. In Section 2, we will introduce the prob-
abilistic framework. The implementation of this framework is discussed in Sec-
tion 3 and applied to the management of diabetes mellitus type 2 in Section 4.
Finally, in Section 5, we conclude and discuss future work.
2 Probabilistic Clinical Model
In this section, the probabilistic model underlying our analysis is introduced.
First, we discuss the model from a symbolic point of view, after which it is
refined with probabilistic aspects.
2.1 Histories
As a point of departure, we look at care as a process that can be modelled as
sequences of possible actions and conditions, that we previously called histories.
An elaborate treatment can be found in [6], where histories were studied from a
more general and theoretical point of view. In short, histories describe sequences
of the state of a patient and interventions being performed on that patient.
Expectations extend histories with possible states in the future, constrained by
clinical management and (patho-)physiological processes. Formally, we define a
history H as a sequence of triples {(pk, ik, tk)}
k=n
k=0 , where pk is a (patient) state,
ik a description of interventions, and tk a time-point from a partially ordered
set. We denote sk for the state consisting of the combination of the patient state
and the performed interventions, i.e., sk = (pk, ik). In this paper, the complete
state is modelled as a set of attribute-value pairs 〈ai, vi〉, where ai is an attribute
and vi the value of that attribute.
The set of all histories is called H. An expectation E extends a history to
other possible histories, i.e., it is a function E : H → P(H), where P(H) denotes
the power set of H, together with some boundary condition (see [6, Chapter
7]) ensuring that these expectations are sound. Sound expectations are step-
functions Es, for which holds that if H
′ ∈ Es(H), for some H that contains n
triples, then H ′ = H ∪ {(pn+1, in+1, tn+1)}, where tn+1 > tn, i.e., Es extends H
with information at a later time-point and at no other time-point.
2.2 Probabilistic histories
The intent of expectations is to describe possible continuations of the history.
Not all of these continuations are equally likely, however. In order to model
this uncertainty, we define a probabilistic expectation as a function Ep which
associates each possible expectation with a probability, i.e.,
Ep : H → P(H× [0, 1])
such that Ep is a step function, i.e., it extends H with just one new time-point
in the future. Furthermore, the set of possible expectations is complete, i.e., if
Ep(H) = {(h1, P1), . . . , (hn, Pn)}, then
∑
Pi = 1.
In the probabilistic model, we assume (i) time-invariance, i.e., the probability
of the expectation only depends on states, but not on the times and (ii) the
expectations are Markovian, that is, expectations depend on the present (the
last state), but not on the past. Note that there are no restrictions to prevent
the embedding of all information about the past in the last state of the history,
except that it will impact the complexity of reasoning. If these two assumptions
are combined, expectations only depend on the final state (sn) of a history, thus
expectation can be described by a transition relation:
sn
P (sn,sn+1)
−−−−−−−→ sn+1
which yields a new history hn+1 = {. . . , (sn, tn), (sn+1, tn+1)}, with tn+1 > tn,
as one of the expectations of the history hn.
To further refine the model, the transition relation is then decomposed ac-
cording to the state decomposition, i.e., the transition of going from v to v′ is
given for all attribute-value 〈a, v〉 pairs such that:
sn, 〈a, v〉
P (c(a,v,v′,sn))
−−−−−−−−−→ 〈a, v′〉
where c(a, v, v′, sn) models a random (choice) variable, which is assumed to be
independent of choices for other attributes in state sn. The complete transition
probability is defined as the conjunction of each of the choices. From this, and
the fact that the choices are independent of each other, we obtain:
P (sn, sn+1) = P (
m∧
i=0
c(ai, vi, v
′
i, sn)) =
m∏
i=1
P (c(ai, vi, v
′
i, sn))
where sn = {〈ai, vi〉}
m
i=0 and sn+1 = {〈ai, v
′
i〉}
m
i=0.
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Fig. 1. General framework of ProbLine. From a patient and intervention model it
generates a discrete-time Markov chain (DTMC), which is used to compute the answer
to a query.
3 ProbLine
3.1 General framework
Probabilistic histories act as a framework for a software tool tool called Prob-
Line. Fig. 1 provides an overview of the approach. ProbLine provides an inter-
face for a patient model as well as an intervention model and answers probabilis-
tic queries in the form P (ai = vi | t), where 〈ai, vi〉 ∈ pi and t a point in time,
i.e., the probability that a patient attribute ai has value vi at time t. ProbLine,
as presented in this paper, is fully implemented and runs on the YAP system,
which is a recent high-performance implementation of Prolog.
The intervention model and patient model describe probabilistic transitions
as formally discussed in the probabilistic clinical model. As the system makes no
other assumptions, different knowledge representation formalisms could be used
to construct intervention and patient models.
Probabilistic histories can be interpreted as infinite discrete-time Markov
chains (DTMC), i.e., a DTMC with a potentially infinite number of states. As
all probabilistic queries are given a time t, and given that there are a finite
number of transitions from a given state, the query can be computed on the
basis of a finite DTMC. The computation of this finite DTMC that can answer
the query is handled by the tool, which then calls the probabilistic symbolic
model checking tool PRISM [9] to compute the answer to the query. This model
checker incorporates state-of-the art symbolic data structures and algorithms for
computing probabilistic queries of complex models.
3.2 Patient model
As far as we are aware, there are no dedicated knowledge representations for
patient models. We therefore use the following basic representation. First, we
can declare new patient attributes as follows:
– patient attribute(+A, +V )
Declares a new attribute A with an initial value V .
– patient attribute(+A, +V, +P )
Declares a new attribute A with possible initial values V (i.e., V is a list)
and a list with probabilities P with a initial probability for each value in V .
activated
inactive
considered
ready
completed
aborted
p
p
p
Fig. 2. Simplified Asbru state chart of [1]. The state transitions that might be prob-
abilistic are indicated by p. The remaining two transitions are technical in the sense
that they are independent of any user interaction. Conditions to go from one state to
the other are not shown in this figure.
The transition system can then be modelled using the following two primitives:
– choice(+A, +V, +V ′, +S, +P )
This corresponds to the choice operator as discussed in the previous section,
where A is an attribute, V is a value, V ′ is an updated value, S is the state,
and P is the probability of making this choice.
– patient av(+S, +A, -V )
Provides the value V of an attribute A in state S.
A graphical representation, for example a flowchart, might be more appropriate
in practice, and can be built on top of these predicates.
3.3 Intervention model
As said, ProbLine is not restricted to a specific knowledge representation. Nev-
ertheless, in order to illustrate its capabilities, we instantiate the intervention
model with a computer-interpretable guideline modelling language. In this work,
we have chosen a small subset of Asbru and modelled its state-chart semantics [1].
A simplified version of the state chart semantics of Asbru is given in Fig. 2. In
the original semantics there are non-deterministic choices to go from one state
to the other, e.g., whether or not to abort a task if the abort condition holds. In
this model, we include the possibility of probabilistic transitions between states.
In particular, the transition from ready to activated, and from activated to some
terminated state, i.e., completed or aborted state, is a probabilistic transition.
These probabilities model the chance that a physician acts if a treatment is
allowed to start or could be terminated.
The representation of tasks, in Asbru they are called plans, is implemented
with the following four predicates:
– plan body(+N, +T, +W, +C)
Defines a new plan with name N , with a body type T (currently either
‘sequential’ or ‘parallel’). This plan has a list of children C and has a wait-
for condition W in order to model optional and mandatory plans for N .
– {abort,complete,filter} condition(+N, +S):
Specifies in which state S the abort/complete/filter condition is true (see [1]).
If it is not specified for a state S, then it is ‘false’ by default because of the
usual Prolog semantics (negation as failure). These conditions influence the
state transitions in the Asbru semantics, e.g., a plan can only abort if the
abort condition holds. Note that arbitrary Prolog programs can be used to
specify when such a condition holds.
The Asbru semantics as mentioned is implemented as a module of ProbLine
and could be extended with other features of the language, e.g., retry conditions
and time-annotations.
4 Diabetes mellitus type 2
In the previous sections, the probabilistic framework of ProbLine, including
its syntax and semantics, have been discussed. In this section, we apply this
framework to the management of diabetes mellitus type 2.
4.1 Management of the disease
It is well known that diabetes type 2 is a complicated disease: various metabolic
control mechanisms are deranged and many different organ systems may be af-
fected by the disorder. Patho-physiologically, there are two main phenomena,
namely, insufficient secretion of the hormone insulin due to a decreased produc-
tion of insulin by B cells in the Langerhans islets of the pancreas, and insulin
resistance in liver, muscle and fat tissue. For the individual patient, there is
a lot of uncertainty to which extent these phenomena occur, which makes it
difficult to predict whether an intervention will be effective. Not only is the
underlying physiology uncertain, choosing which drug to give a patient is also
based on other considerations such as availability, cost, safety, tolerability, and
convenience. Personalised medicine promises a path for individually optimised
treatment choices, but realising this promise will require a more comprehensive
characterisation of disease and drug response.
For diabetes, quite a lot of known about the effect of drugs. In this paper, we
will focus on a well-known biguanide drug called metformin, which is commonly
prescribed as the primary oral anti-diabetic. The dosage that we will consider is
2,000 mg/day, which is for many patients optimal [13]. The efficacy of metformin
2,000 mg/day has also been estimated [3]: the fasting plasma glucose (FPG) will
be lowered up to 86 mg/dL +/- 10 mg/dL (95% confidence interval). The steady-
state situation is not reached before 8 days and a linear reduction of the FPG
seems appropriate [8]. Recently, Shu et al. [14] integrated diverse data supporting
the hypothesis that genetic variations in the encoding of a protein called organic
cation transporter 1 (OCT1) affects the response to metformin. These variants
of OCT1 lead to half of the bio-availability of metformin. It was also estimated
that about 20% of the Caucasian population carries one of these mutations. No
cases are known with multiple mutations, nor is it common for other ethnicities.
plan_body(metformin, sequential, [], []).
abort_condition(metformin,S) :-
patient_av(S, glycemia, hyper),
patient_av(S, metformin_app, T),
T >= 10.
complete_condition(metformin,S) :- patient_av(S, glycemia, normo).
filter_condition(metformin,_).
plan_body(treatment, sequential, [metformin], [metformin]).
abort_condition(treatment, _) :- false.
complete_condition(treatment,_).
filter_condition(treatment,_).
Fig. 3. Model of metformin application in Asbru. The treatment will only be aborted
if the time T ≥ 10, where the time granularity is in days.
4.2 Probabilistic model of metformin pharmokinetics
Given the information above, we estimate a probability distribution for a vari-
able max reduction such that it is a discretised normal variable with mean 86
(mg/dL) and standard deviation 5 as 95% of the population are within 2 stan-
dard deviations (i.e., 10 mg/dL) for a normal distribution. Of course, if the raw
data is available, then other distributions could be used instead. Here we are
limited to the published mean and 95% confidence interval, for which we as-
sume that a bell-shaped distribution is appropriate. Then, to describe expected
probabilities of reaching normoglycemia, we have deterministic transitions:
choice(glycemia, hyper, normo, S, 1) :-
patient av(S, baselineFPG, FGL),
patient av(S, time metformin application, T),
patient av(S, oct1 variant, Oct),
patient av(S, max reduction, Max),
expected normo(FGL, AdT, Max, Oct).
where FPG is a FPG at baseline, T is the time that metformin is applied, and Oct
is a binary variable that is true if the patient has a variation of OCT1 affecting
the efficacy of metformin. The predicate expected normo computes the expected
FPG based on these parameters and returns true if the expected FPG is less
than 110 mg/dL, which is commonly defined as normoglycemia.
4.3 Experiments
Using ProbLine, we can now answer a number of question surrounding the
treatment with metformin. We provide a model of metformin application in
Asbru in Fig. 3 where transition probabilities are set to 0.5 (see Fig. 2).
10 12 14 16 18 20 22 24 26 28 30
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
time (days)
P(
no
rm
og
lyc
em
ia)
 
 
FPG=140, > 7 days
FPG=160, > 7 days
FPG=160, > 14 days
FPG=190, > 14 days
FPG=190, > 21 days
Fig. 4. Probabilistic simulation of metformin application to patients with different
FPG at baseline. Time of metformin application is varied as well.
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Fig. 5. Probabilistic simulation of metformin application to patients with or without
a variation in the OCT1 protein.
Question 1: How long should metformin be applied before it can be decided to
stop the treatment? There is a trade-off here: if the treatment with oral anti-
diabetics is stopped too early then patients may be injecting themselves with
insulin for no good reason; if the treatment is stopped too late, then patients
who need treatment with insulin are not treated appropriately. In Fig. 4, we
plot a number of dose-response curves for different patients (without OCT1
variations). For people with an initial low fasting plasma glucose, the effect of
treatment is relatively quick, whereas people with an initial high fasting plasma
glucose, the effect is much slower and might not be effective at all even after
prolonged treatment.
Question 2: What improvement could we gain using genetic information? As
mentioned, it is hypothesised that the OCT1 protein plays a key role in the
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Fig. 6. Comparing metformin with and without diet in patients with normal OCT1.
efficacy of metformin. This suggests that it would be useful to test whether a
patient has a variation in this gene before treatment. In Fig. 5, two patients are
plotted with the same FPG at baseline but with different OCT1 proteins. On
average, patients in this population (baseline FPG=150) have a good chance
that metformin is effective. However, for the patients with the OCT1-variant,
the chance that metformin is effective is rather small and it might be better to
prescribe an alternative drug. In the end, such pharmacogenetics could be used
for the personalisation of treatments [12].
Question 3: Should we try diet before metformin? In the management of diabetes,
one of the first things that is recommended is a diet. However, the efficacy is
low [5]. If we include this information, then we can ask ProbLine to compare
a treatment with or without a diet. Fig. 6 shows the difference between the
two, where it seems that diet is of little benefit. Of course, there could be other
reasons to recommend a diet, such as improved health or less side-effects of the
treatment. The point is that ProbLine allows for the exploration of different
treatments taking into account uncertainty.
5 Conclusions
In this paper, we presented a new method for the analysis of care processes tak-
ing into account uncertainty. The system implementing this theory, ProbLine,
can handle typical task-network representations of guidelines and flowchart-like
patient models. We presented a case-study in the treatment of diabetes mellitus
type 2 illustrating the strength of this approach.
This work can be extended in several ways. In this paper, we introduced
the core of the language consisting of reasoning with the dynamic aspects of
guidelines, taking into account uncertainty. In future work, we would like to
extend the language with other types of knowledge derived from, for example,
medical ontologies and Bayesian networks. To accomplish this, a more powerful
probabilistic logical language is required, e.g., using one of the recently developed
logics in the field of statistical relational learning (see [4]).
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